Dr. Niesmann And Dr. Othlinghaus GbR — Clinical Trial Site

17 Registered trials

5 Currently recruiting

Organisation

Dr. Niesmann And Dr. Othlinghaus GbR

Location

Bochum, Germany

Identifier

ORG-100045164

Address

Alleestrasse 80, Innenstadt, 44793, Germany

Departments

40893: Hautzentrum im Jahrhunderthaus
Dermatologie
Dermatology
Hautzentrum im Jahrhunderthaus
N/A
NA
Not Applicable
Practice

Clinical trials at this site (17)

Search interface

A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo… Recruiting

2025-520499-24-00 Moderate to Severe Platysma Prominence 5 2025-10-01
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev… Ended

2024-514394-22-00 Actinic Keratosis 6 2022-10-24
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended

2025-522446-51-00 Plaque psoriasis 3 2025-10-17
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 hidradenitis suppurativa (HS) 5 2024-10-02
Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis Ended

2023-509079-18-00 Plaque Psoriasis 3 2024-07-22
A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul… Ended

2023-505487-11-00 Actinic Keratosis on the Face or Scalp 5 2023-12-21
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended

2023-510162-27-00 Chronic venous ulcers (CVU) 4 2021-08-18
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12